{
    "clinical_study": {
        "@rank": "85724", 
        "acronym": "BATARI", 
        "arm_group": [
            {
                "arm_group_label": "no bone anti-resorptive therapy", 
                "arm_group_type": "No Intervention", 
                "description": "(standard of care)"
            }, 
            {
                "arm_group_label": "24-week tx of alendronate/vitamin D", 
                "arm_group_type": "Experimental", 
                "description": "Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D"
            }, 
            {
                "arm_group_label": "Delayed 24-week tx of alendronate/vitamin D", 
                "arm_group_type": "Experimental", 
                "description": "a 24 week delay in initiation of a 24 week course of alendronate/vitamin D"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-site, three-arm, open-label, pilot randomized controlled trial of bone\n      anti-resorptive therapy during ART initiation in HIV-infected adults.  Thirty (30)\n      treatment-na\u00efve HIV-infected adults initiating eligible first-line ART regimens will be\n      randomized in a 1:1:1 fashion to one of the following three arms:\n\n        1. no bone anti-resorptive therapy (standard of care)\n\n        2. concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D;\n\n        3. a 24 week delay in initiation of a 24 week course of alendronate/vitamin D\n\n      Assessments (including clinical evaluation, questionnaires, adherence, basic laboratory\n      evaluation, and BMD measurement) will be performed at baseline, 24 and 48 weeks.  The\n      primary objective will involve calculation of \u03c3 and \u03c1 using all data; \u03b4 will be estimated by\n      comparing the two alendronate arms pooled to the no-treatment arm."
        }, 
        "brief_title": "Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented HIV-1 infection\n\n          -  Adult (aged >18 years or as per local guidelines)\n\n          -  Premenopausal, if female\n\n          -  Antiretroviral-na\u00efve\n\n          -  Starting first-line ART including tenofovir/emtricitabine with either efavirenz\n             (co-formulated as Atripla\u00ae) or elvitegravir, cobicistat (co-formulated as Stribild\u00ae)\n\n          -  Low (<10%) ten-year fracture risk as assessed by the FRAX score validated for\n             Canadian populations\n\n        Exclusion Criteria:\n\n          -  Presence of established osteoporosis at baseline as determined by BMD measurement\n\n          -  Prior or current use of any bone anti-resorptive therapy (eg. bisphosphonate,\n             estrogens with the exception of oral contraceptive pills, etc.)\n\n          -  Inability to communicate in English\n\n          -  Creatinine clearance <35 mL/min (using Cockcroft-Gault formula)\n\n          -  Hypersensitivity to alendronate, other bisphosphonates, or any component of the\n             formulation\n\n          -  Hypocalcemia\n\n          -  Abnormalities of the esophagus which delay esophageal emptying such as stricture or\n             achalasia\n\n          -  Inability to stand or sit upright for at least 30 minutes\n\n          -  Pregnancy, active plans to become pregnant, or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968850", 
            "org_study_id": "CTNPT 021"
        }, 
        "intervention": {
            "arm_group_label": [
                "24-week tx of alendronate/vitamin D", 
                "Delayed 24-week tx of alendronate/vitamin D"
            ], 
            "description": "once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.", 
            "intervention_name": "alendronate/vitamin D", 
            "intervention_type": "Drug", 
            "other_name": "Fosavance 70/56"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Alendronate", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "osteoporosis", 
            "HIV", 
            "bone Mineral Density", 
            "alendronate", 
            "vitamin D"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "darrell.tan@gmail.com", 
                    "last_name": "Darrell Tan, MD", 
                    "phone": "4168646060", 
                    "phone_ext": "77505"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5B 1W8"
                    }, 
                    "name": "St. Michael's Hospital"
                }, 
                "investigator": {
                    "last_name": "Darrell Tan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sharon.walmsley@uhn.com", 
                    "last_name": "Sharon Walmsley, MD", 
                    "phone": "4163403871"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2N2"
                    }, 
                    "name": "Toronto General Hospital"
                }, 
                "investigator": {
                    "last_name": "Sharon Walmsley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial", 
        "overall_contact": {
            "email": "darrell.tan@gmail.com", 
            "last_name": "Darrell Tan, MD", 
            "phone": "4168646060", 
            "phone_ext": "5568"
        }, 
        "overall_official": {
            "affiliation": "St. Michael's Hospital, Toronto", 
            "last_name": "Darrell Tan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary analysis will compare the percentage changes in BMD for the two alendronate/vitamin D arms pooled against the control arm.", 
            "measure": "Percentage changes in BMD at a) the lumbar spine and b) proximal femur", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968850"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of patients who are eligible and who consent to participate will be calculated, and the timeliness (rate) of enrollment will be described, to further inform the feasibility of a larger randomized controlled trial.", 
                "measure": "Feasibility", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Using standardized questions, participants will be asked about the acceptability of the alendronate therapy (including the experience of pill-taking and the weekly schedule)", 
                "measure": "Acceptability", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "As per Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events.", 
                "measure": "Safety/Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Adherence with anti-resorptive therapy will be assessed by pill count and questionnaire.", 
                "measure": "Adherence", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Two bone biomarkers will be assessed: cross-linked carboxyterminal-telopeptide (CTX) and aminoterminal propeptide of type 1 collagen (P1NP).", 
                "measure": "Bone Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "St. Michael's Hospital, Toronto", 
        "sponsors": {
            "collaborator": {
                "agency": "CIHR Canadian HIV Trials Network", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "St. Michael's Hospital, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}